Comparative Pharmacology
Head-to-head clinical analysis: PADCEV versus ZYTIGA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PADCEV versus ZYTIGA.
PADCEV vs ZYTIGA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Enfortumab vedotin is an antibody-drug conjugate (ADC) directed against Nectin-4, a cell adhesion molecule expressed on urothelial carcinoma cells. The antibody portion binds to Nectin-4, leading to internalization and release of the microtubule-disrupting agent monomethyl auristatin E (MMAE) via proteolytic cleavage. MMAE binds to tubulin and inhibits microtubule polymerization, inducing G2/M phase arrest and apoptosis.
Abiraterone acetate is converted in vivo to abiraterone, an androgen biosynthesis inhibitor that selectively inhibits the enzyme CYP17 (17α-hydroxylase/C17,20-lyase). This inhibition blocks androgen production in the testes, adrenal glands, and prostate tumor tissue.
1.25 mg/kg (up to 125 mg) intravenously on days 1, 8, and 15 of a 28-day cycle
1000 mg orally once daily on an empty stomach, at least 1 hour before or 2 hours after a meal, in combination with prednisone 5 mg orally twice daily.
None Documented
None Documented
Approximately 3.4 days (range 2.8-4.2 days) at steady state, supporting every-3-week dosing. Terminal half-life consistent with IgG1 clearance.
The terminal elimination half-life of abiraterone is approximately 12 hours (range 9–18 hours) following oral administration, supporting twice-daily dosing.
Primarily metabolized via catabolism into small peptides and amino acids; minimal renal excretion (<5% unchanged drug in urine). No biliary/fecal data available.
Abiraterone is primarily eliminated via hepatic metabolism with less than 1% excreted unchanged in urine. Approximately 88% of a radiolabeled dose is recovered in feces (mainly as metabolites) and about 5% in urine.
Category C
Category C
Antineoplastic Agent
Antineoplastic Agent